İki Farklı Beyin Kitlesinde Difüzyon MRG’nin Ayırıcı Tanıya Katkısı

Öz

Manyetik rezonans görüntüleme (MRG) santral sinir sistemi (SSS) tümörlerinin tanı, tedavi ve takibinde kullanılan başlıca görüntüleme yöntemidir. SSS tümörlerinin değerlendirilmesinde konvansiyonel görüntüleme yöntemleri yanında suyun hareketinden faydalanılarak elde edilen difüzyon ağırlıklı görüntüleme (DAG) ile görünür difüzyon katsayısı olan Apparent Diffusion Coefficient (ADC) gibi niceliksel difüzyon ölçümleri birçok tümöral lezyonun değerlendirilmesine yardımcı olmaktadır. Konvansiyonel MRG’de T2 ağırlıklı görüntülerde yüksek sinyal özelliği gösteren vazojenik ödem birçok tümör etrafında saptanabilir. Peritümöral vazojenik beyin ödeminden yapılan ölçümler beyin kitlelerinin ayırıcı tanısına yardımcı olabilmektedir. Bu olgu sunumunda glioblastom ve diffüz büyük B hücreli lenfoma tanısı alan olgularda peritümöral vazojenik ödem alanlarından ölçülen ADC değerleri ile difüzyon MRG’nin tümöral lezyonlarda ayırıcı tanıya katkısı değerlendirilecektir.

Anahtar Kelimeler

• Beyin
• Difüzyon
• Kitle
• Manyetik Rezonans Görüntüleme

Contribution to Differential Diagnosis of Diffusion MRI in Two Different Brain Masses

Öz

Magnetic resonance imaging (MRI) is the main imaging method used in the diagnosis, treatment and follow-up of central nervous system (CNS) tumors. In addition to conventional imaging methods in the evaluation of CNS tumors, visible diffusion is detected by diffusion-weighted imaging (DWI) obtained by using the movement of water. Quantitative diffusion measurements such as the Apparent Diffusion Coefficient (ADC) help evaluate many tumoral lesions. On conventional MRI, vasogenic edema, which shows high signal on T2-weighted images, can be detected around many tumors. Measurements made from peritumoral vasogenic brain edema can help in the differential diagnosis of brain masses. In this case report, the contribution of ADC values measured in peritumoral vasogenic edema areas and diffusion MRI to the differential diagnosis of tumoral lesions in cases diagnosed with glioblastoma and diffuse large B-cell lymphoma will be evaluated.

Anahtar Kelimeler

• Brain
• Diffusion
• Mass
• Magnetic Resonance Imaging

Kaynakça

1. 1. Brandao LA, Shiroishi MS, Law M. Brain tumors: a multimodality approach with dif fusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic susceptibility contrast and dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging Clin N Am. 2013;21(2):199-9.
2. 2. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006;239(3):632-49.
3. 3. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro-oncology. 2018;20(suppl_4):iv1-86.
4. 4. Soomro SH, Ting LR, Qing YY, Ren M Molecular biology of glioblastoma: Classification and mutational locations. J Pak Med Assoc. 2017;67(9):1410-4.
5. 5. Marcus HJ, Williams S, Hughes-Hallett A, Camp SJ, Nandi D, Thorne L. Predicting surgical outcome in patients with glioblastoma multiforme using pre-operative magnetic resonance imaging: development and preliminary validation of a grading system. Neurosurgical Review. 2017;40(4):621-31.
6. 6. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410-8.
7. 7. Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32(6):984-92.
8. 8. Gelal F. Difüzyon MR Görüntüleme “ Türk Radyoloji Derneği, Temel Radyoloji Fiziği, Mayıs 2005, İzmir”. Sempozyum Bildiri Kitabı. İnan basım, İzmir, 2005;246-53.

9. 9. Chilla GS, Tan CH, Xu C, Poh CL. Diffusion weighted magnetic resonance imaging and its recent trend-a survey. Quant Imaging Med Surg. 2015;5(3):407-22.
10. 10. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial Mass Lesions: Dynamic Contrast-enhanced Susceptibility-weighted Echoplanar Perfusion MR Imaging. Radiology. 2002;223:11-29.
11. 11. Drevelegas A, Chourmouzi D, Papanicolaou N, Drevelegas K. Malignant Astrocytomas. Handbook of Neuro-Oncology Neuroimaging, Second Edition.421-38.
12. 12. Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. Am J Neuroradiol. 2008;29:471–5.
13. 13. Lee EJ, terBrugge K, Mikulis D, et al. Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions. AJR Am J Roentgenol. 2011;196:71–6.
14. 14. Martín-Noguerol T, Mohan S, Santos-Armentia E, Cabrera-Zubizarreta A, Luna A. Advanced MRI assessment of non-enhancing peritumoral signal abnormality in brain lesions. Eur J Radiol. 2021;143:109900.
15. 15. Server A, Kulle B, Maehlen J, Josefsen R, Schellhorn T, Kumar T, et al. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Acta Radiol. 2009;50:682-9.
16. 16. Ko CC, Tai MH, Li CF, Chen TY, Chen JH, Shu G, et al. Differentiation between Glioblastoma Multiforme and Primary Cerebral Lymphoma: Additional Benefits of Quantitative Diffusion-Weighted MR Imaging. PLoS One. 2016;11(9):e0162565.